Inna V. Dolzhikova - Concepedia

Author

Inna V. Dolzhikova

Ministry of Health of the Russian Federation ORCID

Also Known As

A.V. Kovyrshina, I Dolzhikova, I. V. Dolzhikova, I.V. Dolzhikova, IV Dolzhikova, Inna Dolzhikova, Inna V Dolzhikova, Inna V. Dolzhikova, И. В. Должикова

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Ministry of Health of the Russian Federation Sechenov University Lomonosov Moscow State University Institute of Bioorganic Chemistry Peoples' Friendship University of Russia

About

Inna V. Dolzhikova is an author at Ministry of Health of the Russian Federation specializing in medicine, immunology, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	3.4K
2	Engineering	2	2	97
3	Allergy	2	2	63
4	Biomolecular Engineering	2	2	54
5	Public Health	1	1	28

Inna V. Dolzhikova

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, The Lancet VaccinationVaccine SafetyVaccinologyInterim AnalysisVaccine Development	2021	1.8K
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia Denis Y. Logunov, Inna V. Dolzhikova, Olga V. Zubkova, The Lancet VaccinationVaccine SafetyVaccine DevelopmentImmunologyVirology	2020	1.1K
Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia Inna V. Dolzhikova, Olga V. Zubkova, Amir I. Tukhvatulin, Human Vaccines & Immunotherapeutics	2017	132
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants Vladimir А. Gushchin, Inna V. Dolzhikova, Andrei E. Siniavin, Vaccines Rbd DomainImmunologyVaccine HesitancyCovid-19Vaccine Target	2021	118
SERS-Based Aptasensor for Rapid Quantitative Detection of SARS-CoV-2 Elena Zavyalova, Oganes Ambartsumyan, Gleb Zhdanov, Nanomaterials NanomedicineEngineeringHigh SensitivityViral DiagnosticsBioanalysis	2021	78
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults Amir I. Tukhvatulin, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, The Lancet Regional Health - Europe	2021	71
Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses Amir I. Tukhvatulin, Alina S. Dzharullaeva, Natalia M. Tukhvatulina, PLoS ONE Adaptive Immune SystemInnate Immune SystemImmunologyHumoral ResponseInnate Immunity	2016	43
Virus-Vectored Ebola Vaccines Inna V. Dolzhikova, Elisaveta A. Tokarskaya, Alina S. Dzharullaeva, Acta Naturae VaccinationVaccinologyEbola Virus DiseaseMucosal VaccinationVaccine Development	2017	38
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern I. A. FAVORSKAYA, Dmitry V. Shcheblyakov, I. B. Esmagambetov, Frontiers in Immunology Heterodimeric MoleculeSingle-domain AntibodiesVaccine TargetImmunologyAntiviral Drug Development	2022	35
Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals Daniele Lapa, Daria M. Grousova, Giulia Matusali, Vaccines ImmunodeficienciesImmunologyImmunodominanceOmicron VariantSputnik V-vaccinated Individuals	2022	34

Page 1